Advances in CD30- and PD-1-targeted therapies for classical Hodgkin lymphoma.

about

Advances in CD30- and PD-1-targeted therapies for classical Hodgkin lymphoma.

Item

http://www.wikidata.org/entity/Q52569157

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Advances in CD30- and PD-1-targeted therapies for classical Hodgkin lymphoma.

@en

Advances in CD30- and PD-1-targeted therapies for classical Hodgkin lymphoma.

@nl

type

Item

label

Advances in CD30- and PD-1-targeted therapies for classical Hodgkin lymphoma.

@en

Advances in CD30- and PD-1-targeted therapies for classical Hodgkin lymphoma.

@nl

prefLabel

Advances in CD30- and PD-1-targeted therapies for classical Hodgkin lymphoma.

@en

Advances in CD30- and PD-1-targeted therapies for classical Hodgkin lymphoma.

@nl

P1476

Advances in CD30- and PD-1-targeted therapies for classical Hodgkin lymphoma.

@en

P2093

Grzegorz S Nowakowski

http://www.w3.org/2001/XMLSchema#string

Michael L Wang

http://www.w3.org/2001/XMLSchema#string

Stephen M Ansell

http://www.w3.org/2001/XMLSchema#string

Yucai Wang

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 4.0 International

P2860

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study.

Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation

Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.

Multicenter phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma

Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.

Phase 1 trial of the novel bispecific molecule H22xKi-4 in patients with refractory Hodgkin lymphoma.

Phase I / II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large-cell lymphoma.

Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma.

A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma.

P2888

s13045-018-0601-9

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1186/S13045-018-0601-9

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-04-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1103597810

http://www.w3.org/2001/XMLSchema#string

P698

29685160

http://www.w3.org/2001/XMLSchema#string

P921

Hodgkin's lymphoma

membrane proteins

P932

5914042

http://www.w3.org/2001/XMLSchema#string